癌症的治疗自然疗法

虽然到目前为止，还没有证据证明存在一种能够治愈癌症的神奇的天然物质，但是有些天然疗法已经突显出一些有前景的作用，如作为一种辅助治疗来提高常规治疗（尤其是手术、化疗、放疗）的疗效，以及减轻常规治疗的副作用（尤其是化疗，而放疗的副作用相对轻一些）。不过，在大多数情况下，支持的证据还不是很充分。

癌症自然疗法

参考文献

Wojtowicz-Praga S. Clinical potential of matrix metalloprotease inhibitors. Drugs R D (New Zealand). 1999;1:117-129.
Riviere M, Latreille J, Falardeau P, et al. AE-941 (Neovastat), an inhibitor of angiogenesis: phase I/II cancer clinical trial results. Cancer Invest. 1999;17(suppl 1):16-17.
Jamali M-A, Riviere M, Falardeau P, et al. Effect of AE-941 (Neovastat), an angiogenesis inhibitor, in the Lewis lung carcinoma metastatic model, efficacy, toxicity prevention, and survival. Clin Invest Med. 1998;(suppl):S16.
Riviere M, Falardeau P, Latreille J, et al. Phase I/II lung cancer clinical trial results with AE-941 (Neovastat), an inhibitor of angiogenesis. Clin Invest Med. 1998;(suppl):S14.
Riviere M, Alaoui-Jamali M, Falardeau P, et al. Neovastat: an inhibitor of angiogenesis with anti-cancer activity. Presented at: American Association for Cancer Research Annual Meeting 39; March 28-April 1, 1998; New Orleans, LA.
Blasecki J, Alaoui-Jamali M, Wang T, et al. Oral administration of Neovastat inhibits tumor progression in animal models of progressive tumor growth and metastasis. Int J Oncol. 1997;11(suppl):934.
Dupont E, Alaoui-Jamali M, Wang T, et al. Angiostatic and antitumoral activity of AE-941 (Neovastat), a molecular fraction derived from shark cartilage. Presented at: American Association for Cancer Research Annual Meeting 38; April 12-16, 1997; San Diego, CA.
Horsman MR, Alsner J, Overgaard J. The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma. Acta Oncol. 1998;37:441-445.
Miller DR, Anderson GT, Stark JJ, et al. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol. 1998;16:3649-3655.
Gellert GA, Maxwell RM, Siegel BS. Survival of breast cancer patients receiving adjunctive psychosocial support therapy: a 10-year follow-up study. J Clin Oncol. 1993;11:66-69.
Mausell E, Brisson J, Deschênes L. Social support and survival among women with breast cancer. Cancer. 1995;76:631-637.
Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989;2:888-891.
Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA. 1976;73:3685-3689.
Cameron E, Campbell A. Innovation vs. quality control: an "unpublishable" clinical trial of supplemental ascorbate in incurable cancer. Med Hypotheses. 1991;36:185-189.
Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vit Nutr Res Suppl. 1982;23:103-113.
Lissoni P, Meregalli S, Nosetto L, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology. 1996;53:43-46.
Lissoni P, Paolorossi F, Ardizzoia A, et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res. 1997;23:15-19.
Neri B, de Leonardis V, Gemelli MT, et al. Melatonin as biological response modifier in cancer patients. Anticancer Res. 1998;18:1329-1332.
Cos S, Fernández R, Güézmes A, Sánchez-Barceló EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res. 1998;58:4383-4390.
Lissoni P, Barmo S. Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer. 1995;71:854-856.
Lissoni P, Cazzanga M, Tancini G, et al. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. Eur Urol. 1997;31:178-181.
Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in "high risk" patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q 10. Molec Aspects Med Suppl. 1994;5:S231-S240.
Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q 10. Biochem Biophys Res Comm. 1994;199:1504-1508.
Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q 10 and the regression of metastases. Biochem Biophys Res Comm. 1995;212:172-177.
Rudra PK, Krokan HE. Cell-specific enhancement of doxorubicin toxicity in human tumour cells by docosahexaenoic acid. Anticancer Res. 2001;21:29-38.
Kucuk O, Sarkar FH, Sakr W, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2001;10:861-868.
Hauns B, Haring B, Kohler S, et al. Phase II study with 5-fluorouracil and Ginkgo biloba extract (GBE 761 ONC) in patients with pancreatic cancer. Arzneimittelforschung. 1999;49:1030-1034.
Duda RB, Zhong Y, Navas V, et al. American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth. J Surg Oncol. 1999;72:230-239.
Kupin VI, Polevaia YeB, Sorokin AM. Stimulation of the immunological reactivity of cancer patients by Eleutherococcus extract. Vopr Onkol. 1986;32:21-26.
Daniele B, Perrone F, Gallo C, et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut. 2001;48:28-33.
Unger C, Haring B, Kruse A, et al. Double-blind randomised placebo-controlled phase III study of an E. coli extract plus 5-fluorouracil versus 5-fluorouracil in patients with advanced colorectal cancer. Arzneimittelforschung. 2001;51:332-338.
Mills EED. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. Brit J Cancer. 1988;57:416-417.
Wadleigh RG, Redman RS, Graham ML, et al. Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med. 1992;92:481-484.
Meyer K, Schwartz J, Crater D, et al. Zingiber officinale (ginger) used to prevent 8-Mop associated nausea. Dermatol Nurs. 1995;7:242-244.
Playford RJ, Macdonald CE, Johnson WS. Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. Am J Clin Nutr. 2000;72:5-14.
Holoya PY, Duelge J, Hansen RM,. Prophylaxis of ifosfamide toxicity with oral acetylcysteine. Sem Oncol. 1983;10(suppl 1):66-71.
Slavik M, Saiers JH. Phase I clinical study of acetylcysteine’s preventing ifosfamide-induced hematuria. Sem Oncol. 1983;10(suppl 1):62-65.
Loehrer PJ, Williams SD, Einhorn LH. N-Acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer. Sem Oncol. 1983;10(suppl 1):72-75.
Morgan LR, Donley PJ, Harrison EF. The control of ifosfamide induced hematuria with N-acetylcysteine. Proc Am Assoc Cancer Res. 1981;22:190.
De Blasio F, et al. N-acetyl cysteine (NAC) in preventing nausea and vomiting induced by chemotherapy in patients suffering from inoperable non small cell lung cancer (NSCLC). Chest. 1996;110(suppl 4):103S.
Lissoni P, Tancini G, Barni S, et al. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer. 1997;5:126-129.
Lissoni P, Barni S, Mandalà, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer. 1999;35:1688-1692.
Gaedeke J, Fels LM, Bokemeyer C, et al. Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant. 1996;11:55-62.
Morimoto T, Ogawa M, Orita K, et al. Postoperative adjuvant randomised trial comparing chemo-endocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemo-endocrine Therapy for Breast Cancer (ACETBC) of Japan. Eur J Cancer. 1996;32A:235-242.
Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994;343:1122-1126.
Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother. 1990;31:261-268.
Toi M, Hattori T, Akagi M, et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer. 1992;70:2475-2483.
Mitomi T, Tsuchiya S, Iijima N, et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum. 1992;35:123-130.
Iino Y, Yokoe T, Maemura M, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res. 1995;15:2907-2912.
Bordeleau L, Szalai JP, Ennis M, et al. Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data. J Clin Oncol. 2003;21:1944-1951.
Tsang KW, Lam CL, Yan C, et al. Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer. Respir Med. 2003;97:618-624.
Reiter RJ, Tan DX, Sainz RM, et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol. 2002;54:1299-321.
Shen J, Wenger N, Glaspy J, et al. Electroacupuncture for control of myeloablative chemotherapy-induced emesis: a randomized controlled trial. JAMA. 2000;284:2755-2761.
Dundee JW, Ghaly RG, Fitzpatrick KTJ, et al. Acupuncture prophylaxis of cancer chemotherapy-induced sickness. J R Soc Med. 1988;82:268-271.
Roscoe JA, Morrow GR, Hickok JT, et al. The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study. J Pain Symptom Manage. 2003;26:731-42.
Treish I, Shord S, Valgus J, et al. Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy. Support Care Cancer. June 27, 2003.
Streitberger K, Friedrich-Rust M, Bardenheuer H, et al. Effect of acupuncture compared with placebo-acupuncture at P6 as additional antiemetic prophylaxis in high-dose chemotherapy and autologous peripheral blood stem cell transplantation: a randomized controlled single-blind trial. Clin Cancer Res. 2003;9:2538-2544.
Klein J, Griffiths P. Acupressure for nausea and vomiting in cancer patients receiving chemotherapy. Br J Community Nurs. 2004;9:383-388.
Reiter RJ, Tan DX, Sainz RM, et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol. 2002;54:1299-321.
Schroder FH, Roobol MJ, Boeve ER, et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol. 2005 Oct 17.
Mills E, Wu P, Seely D, et al. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res. 2005;39:360-366.
Roscoe JA, Matteson SE, Morrow GR, et al. Acustimulation wrist bands are not effective for the control of chemotherapy-induced nausea in women with breast cancer. J Pain Symptom Manage. 2005;29:376-384.
Premkumar VG, Yuvaraj S, Vijayasarathy K, et al. Effect of coenzyme Q 10, riboflavin, and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy. Biol Pharm Bull. 2007;30:367-370.
Molassiotis A, Helin AM, Dabbour R, et al. The effects of P6 acupressure in the prophylaxis of chemotherapy-related nausea and vomiting in breast cancer patients. Complement Ther Med. 2007;15:3-12.
Hirose A, Sato E, Fujii H, et al. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol. 2007 Apr 20.
Cowawintaweewat S, Manoromana S, Sriplung H, et al. Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. Asian Pac J Allergy Immunol. 2006;24:33-45.
deVere White RW, Hackman RM, Soares SE, et al. Effects of a mushroom mycelium extract on the treatment of prostate cancer. Urology. 2002;60:640-644.
Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007 Sep 25.
Vaishampayan U, Hussain M, Banerjee M, et al. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer. 2007;59:1-7.
Molassiotis A, Sylt P, Diggins H. The management of cancer-related fatigue after chemotherapy with acupuncture and acupressure: A randomised controlled trial. Complement Ther Med. 2007;15:228-237.
Lee J, Dodd M, Dibble S, et al. Review of acupressure studies for chemotherapy-induced nausea and vomiting control. J Pain Symptom Manage. 2008 Apr 25.
Block KI, Koch AC, Mead MN, et al. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer. 2008;123:1227-1239.

最后修改日期 : 2017-2-14

疾病自然疗法

相关专题

癌症的治疗自然疗法